High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors.

Area of Science:

• Endocrinology
• Molecular Biology
• Cancer Research

Background:

• Epigenetic modifications, including chromatin changes, are implicated in pituitary neoplasia.
• These alterations affect tumor suppressor and oncogene expression and may be reversible.
• The specific role of histone deacetylases (HDACs) in pituitary tumorigenesis remains unclear.

Purpose of the Study:

• To investigate the expression of Class I HDACs in non-functioning pituitary adenomas (NFPAs).
• To evaluate the therapeutic potential of targeting HDACs and DNA methylation in NFPAs.

Main Methods:

• RT-PCR and immunohistochemical staining (IHC) to assess HDAC2 and HDAC3 expression in NFPAs versus normal pituitary (NP) samples.
• In vitro treatment of a human NFPA cell line (PDFS) with an HDAC3 inhibitor (RGFP966) and a DNA methyltransferase (DNMT) inhibitor (5'-aza-2'-deoxycytidine).
• Assessment of cell proliferation and tumor suppressor gene expression (STAT1, P16, PTEN, MEG3).

Main Results:

• HDAC2 and HDAC3 were significantly upregulated in NFPAs compared to NP samples.
• HDAC3 inhibition with RGFP966 reduced PDFS cell proliferation by 70%.
• Combined inhibition of HDAC3 and DNMT restored expression of tumor suppressor genes STAT1, P16, PTEN, and MEG3.

Conclusions:

• Both histone modification and DNA methylation are involved in the pathogenesis of human NFPAs.
• Targeting HDACs and DNA methylation represents a promising therapeutic strategy for NFPAs.